Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Ways2Capital Equity Update : Shilpa Medicare Rises 3% On USFDA Approval For Imatinib Mesylate Tablets

Shares of Shilpa Medicare rose 3.8 percent intraday Friday after company received US Food and Drug Administration (USFDA) approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg.

Imatinib Mesylate Tablets is a generic equivalent of the reference listed drug (RLD), gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended in the label approved by FDA.

As per IQVIA MAT Q2 2018 data, the US market for Imatinib Mesylate Tablets is approximately USD 885 million.

For more details click here – https://www.ways2capital.com



This post first appeared on After Italy Verdict Gold Trades Higher On Safe-haven Demands; Silver Down, please read the originial post: here

Share the post

Ways2Capital Equity Update : Shilpa Medicare Rises 3% On USFDA Approval For Imatinib Mesylate Tablets

×

Subscribe to After Italy Verdict Gold Trades Higher On Safe-haven Demands; Silver Down

Get updates delivered right to your inbox!

Thank you for your subscription

×